[ad_1]
This was revealed by the website of the Russian Fund for Direct Investments. RDIF “From the Russian government today, the results of the Russian Corona virus vaccine, Sputnik, which was developed by a research institute Gamalya According to the results of the first analysis of the data from the third phase of the vaccine trials, it achieved an effectiveness of 92%, according to the website of the Russian Investment Fund.
The site said 40,000 volunteers are currently participating in the third phase of a double-blind, randomized, controlled clinical trial, in which more than 20,000 of them were vaccinated with the first dose of the vaccine and more than 16,000 with the first and second dose of the vaccine..
The uniqueness of the Russian vaccine is the use of two different types of human adenovirus vectors that allow for a strong and long-term immune response after the second injection..
The Russian Sputnik vaccine is approvedSputnik V On a well-researched human adenovirus vector platform, which has been shown to be safe and effective with no long-term side effects in over 250 clinical trials worldwide, conducted over the past two decades, “while the history of the use of human adenoviruses in vaccine development was in 1953.
Clinical trials of the third phase of the Russian Sputnik vaccine are currently approved Sputnik V The coronavirus is currently underway in Belarus, the United Arab Emirates, Venezuela and other countries, as well as the second and third stages in India..
.
[ad_2]
Source link
